Visit to Israel by the delegation of China Pharmaceutical Promotion Association (Series 1)

Source: on May 27, 2016, at the invitation of the Ministry of economy of Israel, 13 members of the delegation led by Jiang Hualiang, President of China Pharmaceutical Association, director of Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences, and song Ruilin, executive president of China Pharmaceutical Association, arrived in Israel for a visit on May 26 On the afternoon of the arrival, the delegation visited the office of chief scientist, Israel innovation authority in Tel Aviv Mr avi luvton, executive director of Asia Pacific region of Israel innovation Bureau, and MS merav Tapiero, project director of China Israel industrial R & D cooperation program, warmly welcomed the visit of the delegation of China Council for the promotion of drugs During the talks, President Jiang Hualiang first introduced the basic situation of the China Council for the promotion of drugs and the main purpose of the delegation's visit He said that under the current background of innovation and exchanges between China and Israel, the two sides have broad prospects for cooperation Song Ruilin, executive chairman, said that Israel has a lot of valuable experience in biomedical innovation, which is worth learning from the Chinese pharmaceutical industry On the one hand, the Israeli government's policy environment for supporting pharmaceutical innovation is worthy of our study and reference; on the other hand, China and Israel also have extensive cooperation opportunities in the field of technological innovation and investment Mr avi luvton introduced the establishment background, development process and functions of the innovation Bureau of Israel in detail In the 1870s, the Israeli government realized the importance of scientific and technological innovation and hoped to promote the development of the national economy with the establishment of the institution Its main function is to help the society and enterprises to carry out commercial research and development, promote the application of high and new technology, and provide risk support for the transformation of technological achievements At present, the funds are mainly used in four parts: universities and scientific research institutions, early start-ups, R & D centers, and international cooperation Subsequently, representatives of the two sides had in-depth exchanges on some specific issues of China Israel cooperation, and the atmosphere of the whole meeting was warm The members of the delegation have a more comprehensive understanding of the relevant policies of the Israeli government to encourage innovation, and have a more intuitive understanding of the Israeli pharmaceutical industry, which has yielded a lot     Zhang Chenghai, chairman of Meiluo pharmaceutical, he Yun, general manager of Liangjiang pharmaceutical R & D center, Zheng Qiang, director of Chengdu Kanghong pharmaceutical enterprise technology center, song Tingting, project director of Jiangsu aosaikang pharmaceutical, Zhao Xiaobin, project expert of Zhejiang Pharmaceutical International, Gu Hongmei, assistant president of Zhengda Tianqing pharmaceutical, PU Daojun, assistant general manager of Southwest Pharmaceutical, Feng Wanyu, director of Pharmaceutical Department of Peking University People's Hospital, Si Zhang Kaiyang, assistant general manager of chuanjiuzhang biology, Wang Xin, deputy director of China pharmaceutical promotion association, Ruan Xinxin, project manager, etc attended the above activities Meeting site